Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.

$599
Posted in: GLP-1RA Mar 27 | 2020FENIX Analysis: Ozempic and Trulicity CV Indication Initial PromotionPurchase Blast
$599
Posted in: Glucose Monitoring Mar 26 | 2020Senseonics Suspends US Commercial Sales to New PatientsPurchase Blast
$599
Posted in: Other Mar 25 | 2020AZ Partners with Silence Therapeutics for siRNA Targeting; AZ Leverages BrightInsight for Digital PlatformPurchase Blast
$599
Posted in: Glucose Monitoring Mar 24 | 2020DarioHealth Partners with Vitality GroupPurchase Blast
$599
Posted in: Glucose Monitoring Mar 23 | 2020Senseonics Exploring Strategic AlternativesPurchase Blast
$599
Posted in: Dual/triple agonist, Other Mar 23 | 2020BI Returns Amylin Analog WW Rights to ZealandPurchase Blast
$599
Posted in: Bolus Insulin, GLP-1RA Mar 23 | 2020CHMP Agenda March 23-26; Lilly Halts Trial Enrollments Over COVID-19 ConcernsPurchase Blast
$599
Posted in: Glucagon, Insulin Delivery, Other Mar 20 | 2020Glooko Enables Free Remote Care Solution; Hovorka’s AP App Launched in UK; Valeritas Receives Court Approval on Zealand SalePurchase Blast
$599
Posted in: Bolus Insulin, Glucagon Mar 19 | 2020Xeris Home Delivery via Amazon; Oramed End-of-Ph2 FDA FeedbackPurchase Blast
$599
Posted in: Other Mar 18 | 2020Medtronic To Move Away From Its Non-Intensive Diabetes StrategyPurchase Blast
$599
Posted in: Glucose Monitoring Mar 18 | 2020Nemaura to Use Wellness Category for US CGM LaunchPurchase Blast
$599
Posted in: Glucose Monitoring, Other Mar 17 | 2020DarioHealth Q4 '19 Earnings UpdatePurchase Blast
$599
Posted in: DPP-IVi, Other Mar 17 | 2020Mylan/Aurobindo Invalidates Two Tradjenta Patents; PRV-031 (Teplizumab) Ph3 PROTECT Trial PausedPurchase Blast
$599
Posted in: SGLT2i Mar 12 | 2020Zyquista T1DM CRL stands (Lexicon Q4 '19 Earnings Update); Jardiance CKD Fast Track DesignationPurchase Blast